<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129233</url>
  </required_header>
  <id_info>
    <org_study_id>169</org_study_id>
    <nct_id>NCT00129233</nct_id>
  </id_info>
  <brief_title>Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance</brief_title>
  <official_title>The Novel Antihypertensive Goal Of hYpertension With diAbetes ― Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nagoya University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Various guidelines recommended angiotensin converting enzyme (ACE) inhibitors or angiotensin
      Ⅱ receptor-1 blockers (ARBs) for hypertensive patients with diabetes on the basis of the
      cardiac- and reno-protective effects of these drugs. However, these recommendations could not
      be extrapolated to Japanese patients, because Japan has been known as a country with a low
      incidence of coronary artery disease and a high incidence of cerebrovascular disease.
      Furthermore, calcium channel blockers (CCBs) also were protective against renal function as
      well as ACE inhibitors in Japanese diabetic hypertensive patients. This study will test
      whether ARBs or CCBs are superior in treating Japanese diabetic hypertensive patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite cardiovascular events including fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, admission due to heart failure, coronary intervention and sudden cardiac death</measure>
    <time_frame>At least 3 years of mean follow up period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>total death</measure>
    <time_frame>At least 3 years of mean follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac function evaluated by ultrasonography</measure>
    <time_frame>At least 3 years of mean follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of atrial fibrillation/flutter</measure>
    <time_frame>At least 3 years of mean follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>control of blood glucose</measure>
    <time_frame>At least 3 years of mean follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>At least 3 years of mean follow up period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1150</enrollment>
  <condition>Hypertension</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan group treated with 80-160mg daily valsartan without Ca channel blockers or ACE inhibitors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine group treated with 5-10mg daily amlodipine without ACE inhibitors or angiotensin receptor blockers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>valsartan 80 to 160 mg daily</description>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine 5 to 10 mg daily.</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of hypertension

          -  Clinical diagnosis of type 2 diabetes or impaired glucose tolerance

        Exclusion Criteria:

          -  History of congestive heart failure, myocardial infarction, or coronary
             revascularization in the recent 6 months.

          -  Taking calcium channel blocker for the purpose of angina pectoris

          -  Reduced ejection fraction (&lt; 40%)

          -  Second- or third-degree of atrioventricular block

          -  Severe hypertension (&gt; 200/110 mmHg) or secondary hypertension

          -  History of stroke in the recent 6 months

          -  Serum creatinine &gt; 2.5 mg/dl

          -  Estimated survival duration less than 3 years due to other conditions

          -  Pregnant woman or possibly pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toyoaki Murohara, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Nagoya University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Nagoya University Graduate School of Medicine</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004 Jun 19;363(9426):2022-31.</citation>
    <PMID>15207952</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2005</study_first_submitted>
  <study_first_submitted_qc>August 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2005</study_first_posted>
  <last_update_submitted>April 29, 2013</last_update_submitted>
  <last_update_submitted_qc>April 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nagoya University</investigator_affiliation>
    <investigator_full_name>TOYOAKI MUROHARA</investigator_full_name>
    <investigator_title>Proffesor</investigator_title>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>rennin-angiotensin system</keyword>
  <keyword>calcium channel blocker</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

